Middle East IVF Market Driven by High Demand for IVF and Related Treatments
By LabMedica International staff writers Posted on 23 Jan 2019 |
The global In Vitro Fertilization (IVF) market is currently estimated to be worth between USD 10 billion to USD 12 billion, while the IVF market in Middle East & North Africa (MENA) is estimated to be approximately USD 1 billion, indicating a high demand for IVF and related treatments in the region.
These are the findings in a new report published by Colliers International (Toronto, Canada) as part of the MEDLAB Market Report series ahead of MEDLAB 2019, which took place from February 4-7, 2019, at the Dubai World Trade Centre. MEDLAB Exhibition & Congress 2019, which is organized by Informa Exhibitions, welcomed more than 19,600 medical laboratory trade professionals and 670+ exhibitors from 46 countries in an effort to develop the value of laboratory medicine in shaping the future of healthcare and to provide advanced medical laboratory techniques for better health.
According to the latest report by Colliers International, the population in MENA has increased from over 100 million in 1950 to 380 million in 2017 and is expected to increase to 700 million by 2050, although the overall fertility rates in the region have decreased from seven children per women in 1960 to just three in 2017. Infertility in the MENA region is 15% or higher, as compared to 10% worldwide, with male infertility being a growing problem and occurring in approximately 50% of the cases in the GCC and Middle East. This can be attributed to lifestyle, diabetes, obesity and genetics related factors, as GCC countries have one of the highest diabetic and obesity rates in the world.
However, new innovations and improved testing techniques are gradually creating paradigm shifts in the field of assisted reproductive technology. In particular, increased focus on pre-marital screening for consanguineous (relatives) couples and development of new genetic tests for screening of embryos greatly improves the chance of minimizing certain genetic diseases common in this region.
“The Carrier Genetic Test (CGT) helps to determine the risk of having a child with a genetic disease. Anyone, without knowing, can be a carrier of one or more recessive mutations, but some couples have higher possibilities to carry the same genes,” said Dr. Laura Melado, Specialist – Obstetrics & Gynecology, IVF, IVI Middle East Fertility Clinic, Abu Dhabi, UAE, who will be speaking at the Cytogenetics & IVF Conference during MEDLAB 2019, commented. “When this happens Pre-implantation Genetic Testing (PGD) can be done for the embryos as part of the fertility treatment to help the couples to deliver healthy babies.”
“IVF is not only sought after locally but is one of the leading treatments undertaken by medical tourists in the UAE, especially in Dubai. Based on Colliers’ discussions with leading operators, medical tourism accounts for 10% to 15% of the IVF patient volumes,” said Mansoor Ahmed, Director Healthcare, Education & PPP for MENA Region at Colliers International.
Related Links:
Colliers International
These are the findings in a new report published by Colliers International (Toronto, Canada) as part of the MEDLAB Market Report series ahead of MEDLAB 2019, which took place from February 4-7, 2019, at the Dubai World Trade Centre. MEDLAB Exhibition & Congress 2019, which is organized by Informa Exhibitions, welcomed more than 19,600 medical laboratory trade professionals and 670+ exhibitors from 46 countries in an effort to develop the value of laboratory medicine in shaping the future of healthcare and to provide advanced medical laboratory techniques for better health.
According to the latest report by Colliers International, the population in MENA has increased from over 100 million in 1950 to 380 million in 2017 and is expected to increase to 700 million by 2050, although the overall fertility rates in the region have decreased from seven children per women in 1960 to just three in 2017. Infertility in the MENA region is 15% or higher, as compared to 10% worldwide, with male infertility being a growing problem and occurring in approximately 50% of the cases in the GCC and Middle East. This can be attributed to lifestyle, diabetes, obesity and genetics related factors, as GCC countries have one of the highest diabetic and obesity rates in the world.
However, new innovations and improved testing techniques are gradually creating paradigm shifts in the field of assisted reproductive technology. In particular, increased focus on pre-marital screening for consanguineous (relatives) couples and development of new genetic tests for screening of embryos greatly improves the chance of minimizing certain genetic diseases common in this region.
“The Carrier Genetic Test (CGT) helps to determine the risk of having a child with a genetic disease. Anyone, without knowing, can be a carrier of one or more recessive mutations, but some couples have higher possibilities to carry the same genes,” said Dr. Laura Melado, Specialist – Obstetrics & Gynecology, IVF, IVI Middle East Fertility Clinic, Abu Dhabi, UAE, who will be speaking at the Cytogenetics & IVF Conference during MEDLAB 2019, commented. “When this happens Pre-implantation Genetic Testing (PGD) can be done for the embryos as part of the fertility treatment to help the couples to deliver healthy babies.”
“IVF is not only sought after locally but is one of the leading treatments undertaken by medical tourists in the UAE, especially in Dubai. Based on Colliers’ discussions with leading operators, medical tourism accounts for 10% to 15% of the IVF patient volumes,” said Mansoor Ahmed, Director Healthcare, Education & PPP for MENA Region at Colliers International.
Related Links:
Colliers International
Latest Industry News
- Thermo Fisher and Bio-Techne Enter Into Strategic Distribution Agreement for Europe
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus